The Alliance of Specialty Medicine wrote to the leadership in the Senate and House regarding the Biosimilar Red Tape Elimination Act (S.2305). The Alliance voiced concerns that the legislation would establish a presumption that an approved biosimilar product may be deemed interchangeable with the reference biologic product without requiring additional switching studies by the biopharmaceutical manufacturer. The Alliance also cautioned that once a biosimilar is deemed interchangeable, health plans may indiscriminately switch patients back and forth between medications depending on whichever drug has a formulary preference and delivers the most lucrative rebate. The letter can be accessed by clicking the link below.
Alliance Letter – Biosimilar Red Tape Elimination Act (S. 2305)
